Hepatitis B Immune Globulin Clinical Trials For HBV Prevention In Liver Transplant Patients To Be Discussed By Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
Nabi Pharmaceuticals expects FDA action on Nabi-HB immune globulin BLA by mid-2004. Committee will also discuss supplemental testing for HIV and HCV, and platelet apheresis quality control.
You may also be interested in...
Hepatitis B Immune Globulin I.V. Approval Could Rely On Open-Label Studies, Historical Controls – FDA
The agency's briefing materials for the March 18 meeting of the Blood Products Advisory Committee note that prospective trials could be difficult because HBIGIV is currently used off-label in combination with antiviral drugs.
FDA Antihypertensive Draft Class Labeling To Be Reviewed By Cardio-Renal Committee
FDA’s proposal for relabeling of antihypertensive agents is based on prior recommendations by the committee that information on cardiovascular outcomes related to blood pressure lowering be included as class labeling.